Literature DB >> 19147735

Rapid flow cytometry-based structural maintenance of chromosomes 1 (SMC1) phosphorylation assay for identification of ataxia-telangiectasia homozygotes and heterozygotes.

Shareef A Nahas1, Anthony W Butch, Liutao Du, Richard A Gatti.   

Abstract

BACKGROUND: No rapid reliable method exists for identifying ataxia-telangiectasia (A-T) homozygotes or heterozygotes. Heterozygotes are at an increased risk of cancer and are more sensitive to the effects of ionizing radiation (IR) than the general population. We report a rapid flow cytometry (FC)-based ataxia-telangiectasia mutated (ATM) kinase assay that measures ATM- dependent phosphorylation of structural maintenance of chromosomes 1 (SMC1) following DNA damage (FC-pSMC1 assay).
METHODS: After optimizing conditions with lymphoblastoid cell lines (LCLs), we studied peripheral blood mononuclear cells (PBMCs) isolated from 16 healthy donors (unknowns), 10 obligate A-T heterozygotes, and 6 unrelated A-T patients. One hour after DNA damage (by either IR or bleomycin), the cells were fixed and incubated with a primary antibody to SMC1pSer966. We analyzed the stained cells by FC to determine the difference in geometric mean fluorescence intensity (DeltaGMFI) of untreated and treated cells; this difference was expressed as a percentage of daily experimental controls.
RESULTS: The FC-pSMC1 assay reliably distinguished ATM heterozygotes and homozygotes from controls. Average DeltaGMFI percentages (SD) of daily controls were, for unknowns, 106.1 (37.6); for A-T heterozygotes, 37.0 (18.7); and for A-T homozygotes; -8.73 (16.2). Values for heterozygotes and homozygotes were significantly different from those of controls (P < 0.0001).
CONCLUSIONS: The FC-pSMC1 assay shortens the turnaround time for diagnosing A-T homozygotes from approximately 3 months to approximately 3 h. It also identifies A-T heterozygotes and can be used for prenatal counseling or for screening individuals in large study cohorts for potential ATM heterozygosity, which can then be confirmed by sequencing.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19147735      PMCID: PMC2980758          DOI: 10.1373/clinchem.2008.107128

Source DB:  PubMed          Journal:  Clin Chem        ISSN: 0009-9147            Impact factor:   8.327


  33 in total

1.  Phosphorylation of SMC1 is a critical downstream event in the ATM-NBS1-BRCA1 pathway.

Authors:  Risa Kitagawa; Christopher J Bakkenist; Peter J McKinnon; Michael B Kastan
Journal:  Genes Dev       Date:  2004-06-02       Impact factor: 11.361

2.  Improved diagnostic testing for ataxia-telangiectasia by immunoblotting of nuclear lysates for ATM protein expression.

Authors:  Helen H Chun; Xia Sun; Shareef A Nahas; Sharon Teraoka; Chih Hung Lai; Patrick Concannon; Richard A Gatti
Journal:  Mol Genet Metab       Date:  2003-12       Impact factor: 4.797

Review 3.  Ataxia-telangiectasia: diagnosis and treatment.

Authors:  Susan Perlman; Sara Becker-Catania; Richard A Gatti
Journal:  Semin Pediatr Neurol       Date:  2003-09       Impact factor: 1.636

4.  Assessment of chronic gamma radiosensitivity as an in vitro assay for heterozygote identification of ataxia-telangiectasia.

Authors:  D E Weeks; M C Paterson; K Lange; B Andrais; R C Davis; F Yoder; R A Gatti
Journal:  Radiat Res       Date:  1991-10       Impact factor: 2.841

5.  ATM protein purified from vaccinia virus expression system: DNA binding requirements for kinase activation.

Authors:  Helen H Chun; Robert B Cary; Fredrick Lansigan; Julian Whitelegge; David J Rawlings; Richard A Gatti
Journal:  Biochem Biophys Res Commun       Date:  2004-09-10       Impact factor: 3.575

6.  ATM and DNA-PK function redundantly to phosphorylate H2AX after exposure to ionizing radiation.

Authors:  Tom Stiff; Mark O'Driscoll; Nicole Rief; Kuniyoshi Iwabuchi; Markus Löbrich; Penny A Jeggo
Journal:  Cancer Res       Date:  2004-04-01       Impact factor: 12.701

7.  Phosphorylation of histone H2AX as a measure of radiosensitivity.

Authors:  Peggy L Olive; Judit P Banáth
Journal:  Int J Radiat Oncol Biol Phys       Date:  2004-02-01       Impact factor: 7.038

8.  Contributions of ATM mutations to familial breast and ovarian cancer.

Authors:  Yvonne R Thorstenson; Adriane Roxas; Regina Kroiss; Mark A Jenkins; Kristine M Yu; Thomas Bachrich; Daniela Muhr; Tierney L Wayne; Gilbert Chu; Ronald W Davis; Teresa M U Wagner; Peter J Oefner
Journal:  Cancer Res       Date:  2003-06-15       Impact factor: 12.701

9.  Functional and computational assessment of missense variants in the ataxia-telangiectasia mutated (ATM) gene: mutations with increased cancer risk.

Authors:  M Mitui; S A Nahas; L T Du; Z Yang; C H Lai; K Nakamura; S Arroyo; S Scott; A Purayidom; P Concannon; M Lavin; R A Gatti
Journal:  Hum Mutat       Date:  2009-01       Impact factor: 4.878

10.  Localization of an ataxia-telangiectasia gene to chromosome 11q22-23.

Authors:  R A Gatti; I Berkel; E Boder; G Braedt; P Charmley; P Concannon; F Ersoy; T Foroud; N G Jaspers; K Lange
Journal:  Nature       Date:  1988-12-08       Impact factor: 49.962

View more
  17 in total

1.  Functional characterization and targeted correction of ATM mutations identified in Japanese patients with ataxia-telangiectasia.

Authors:  Kotoka Nakamura; Liutao Du; Rashmi Tunuguntla; Francesca Fike; Simona Cavalieri; Tomohiro Morio; Shuki Mizutani; Alfredo Brusco; Richard A Gatti
Journal:  Hum Mutat       Date:  2011-11-09       Impact factor: 4.878

Review 2.  Clinical radiation sensitivity with DNA repair disorders: an overview.

Authors:  Julianne M Pollard; Richard A Gatti
Journal:  Int J Radiat Oncol Biol Phys       Date:  2009-08-01       Impact factor: 7.038

3.  SMRT compounds abrogate cellular phenotypes of ataxia telangiectasia in neural derivatives of patient-specific hiPSCs.

Authors:  Peiyee Lee; Nathan T Martin; Kotoka Nakamura; Soheila Azghadi; Mandana Amiri; Uri Ben-David; Susan Perlman; Richard A Gatti; Hailiang Hu; William E Lowry
Journal:  Nat Commun       Date:  2013       Impact factor: 14.919

Review 4.  SMRT compounds correct nonsense mutations in primary immunodeficiency and other genetic models.

Authors:  Richard A Gatti
Journal:  Ann N Y Acad Sci       Date:  2012-02       Impact factor: 5.691

5.  Application of a radiosensitivity flow assay in a patient with DNA ligase 4 deficiency.

Authors:  David Buchbinder; Matthew J Smith; Misako Kawahara; Morton J Cowan; Jeffrey S Buzby; Roshini S Abraham
Journal:  Blood Adv       Date:  2018-08-14

6.  p53 centrosomal localization diagnoses ataxia-telangiectasia homozygotes and heterozygotes.

Authors:  Andrea Prodosmo; Andrea De Amicis; Cecilia Nisticò; Mario Gabriele; Giuliana Di Rocco; Laura Monteonofrio; Maria Piane; Enrico Cundari; Luciana Chessa; Silvia Soddu
Journal:  J Clin Invest       Date:  2013-02-01       Impact factor: 14.808

7.  ATM is down-regulated by N-Myc-regulated microRNA-421.

Authors:  Hailiang Hu; Liutao Du; Gindy Nagabayashi; Robert C Seeger; Richard A Gatti
Journal:  Proc Natl Acad Sci U S A       Date:  2010-01-04       Impact factor: 11.205

8.  A new series of small molecular weight compounds induce read through of all three types of nonsense mutations in the ATM gene.

Authors:  Liutao Du; Michael E Jung; Robert Damoiseaux; Gladys Completo; Francesca Fike; Jin-Mo Ku; Shareef Nahas; Cijing Piao; Hailiang Hu; Richard A Gatti
Journal:  Mol Ther       Date:  2013-06-18       Impact factor: 11.454

9.  A proposed bailout for A-T patients?

Authors:  Richard A Gatti; Susan Perlman
Journal:  Eur J Neurol       Date:  2009-06       Impact factor: 6.089

10.  Nonaminoglycoside compounds induce readthrough of nonsense mutations.

Authors:  Liutao Du; Robert Damoiseaux; Shareef Nahas; Kun Gao; Hailiang Hu; Julianne M Pollard; Jimena Goldstine; Michael E Jung; Susanne M Henning; Carmen Bertoni; Richard A Gatti
Journal:  J Exp Med       Date:  2009-09-21       Impact factor: 14.307

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.